Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab.

Neurol Neuroimmunol Neuroinflamm

From the Department of Neurology (V.F.M.F., J.M.S.); and Department of Pathology (D.M.), Brigham and Women's Hospital, Partners MS Center, Harvard Medical School, Boston, MA.

Published: September 2019

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705626PMC
http://dx.doi.org/10.1212/NXI.0000000000000589DOI Listing

Publication Analysis

Top Keywords

tumefactive demyelination
4
demyelination patient
4
patient relapsing-remitting
4
relapsing-remitting ocrelizumab
4
tumefactive
1
patient
1
relapsing-remitting
1
ocrelizumab
1

Similar Publications

Deep learning MRI models for the differential diagnosis of tumefactive demyelination versus -wildtype glioblastoma.

AJNR Am J Neuroradiol

January 2025

From the Department of Radiology (GMC, MM, YN, BJE), Department of Quantitative Health Sciences (PAD, MLK, JEEP), Department of Neurology (CBM, JAS, MWR, FSG, HKP, DHL, WOT), Department of Neurosurgery (TCB), Department of Laboratory Medicine and Pathology (RBJ), and Center for Multiple Sclerosis and Autoimmune Neurology (WOT), Mayo Clinic, Rochester, MN, USA; Dell Medical School (MFE), University of Texas, Austin, TX, USA.

Background And Purpose: Diagnosis of tumefactive demyelination can be challenging. The diagnosis of indeterminate brain lesions on MRI often requires tissue confirmation via brain biopsy. Noninvasive methods for accurate diagnosis of tumor and non-tumor etiologies allows for tailored therapy, optimal tumor control, and a reduced risk of iatrogenic morbidity and mortality.

View Article and Find Full Text PDF

Background: Few studies have examined B cells among patients with anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), including brain pathology.

Objective: To describe cases of tumefactive MOGAD with B-cell dominant central nervous system (CNS) infiltration.

Methods: In this study, we reviewed three cases with clinical and brain histopathological features with tumefactive MOGAD.

View Article and Find Full Text PDF

Objective: Differentiating intramedullary spinal cord tumor (IMSCT) from spinal cord tumefactive demyelinating lesion (scTDL) remains challenging with standard diagnostic approaches. This study aims to develop and evaluate the effectiveness of a magnetic resonance imaging (MRI)-based radiomics model for distinguishing scTDL from IMSCT before treatment initiation.

Methods: A total of 75 patients were analyzed in this retrospective study, comprising 55 with IMSCT and 20 with scTDL.

View Article and Find Full Text PDF

Etiology and characteristics of pseudotumoral lesions and tumefactive demyelination in multiple sclerosis.

Mult Scler Relat Disord

December 2024

Faculty of Medicine, University of Belgrade, Serbia; Neurology Clinic, University Clinical Center of Serbia, Serbia. Electronic address:

Article Synopsis
  • The study focused on cerebral pseudotumoral lesions (CPTL) greater than 2 cm, primarily in patients referred for evaluation of multiple sclerosis (MS).
  • Most of the 75 patients studied had MS (58.7%), with relapsing disease and specific lesion characteristics being significantly more common in this group compared to non-MS patients.
  • Key indicators such as headache, the nature of disease progression, and certain MRI traits could help differentiate between MS and non-MS conditions, suggesting a need for further research with larger sample sizes.
View Article and Find Full Text PDF
Article Synopsis
  • Acute Hemorrhagic Leukoencephalitis (AHLE) is a rare, fast-progressing brain condition characterized by severe inflammation and hemorrhage, often triggered by infections, with a high mortality rate and significant disability for survivors.
  • A case study of a 46-year-old woman with chronic hepatitis B revealed she experienced neurological symptoms, initially misdiagnosed as demyelination, but later confirmed as AHLE after further MRI scans showed hemorrhagic lesions.
  • The patient's eventual recovery, despite severe initial symptoms, underscores the importance of early detection and aggressive treatment in improving outcomes for patients with AHLE linked to chronic viral infections.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!